Transcriptome modeling and phenotypic assays for cancer precision medicine

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Precision cancer medicine relies on actionable biomarkers for patient stratification and outcome prediction.
• Current reliance on genetic mutations as biomarkers is limited by low frequency and varied profiles across cancer types.
• Thousands of cancer-associated mutated genes identified lack clinical utility as predictive biomarkers.

Purpose of the Study:

• To explore the potential of transcriptome and phenotypic screening data for identifying novel non-genetic biomarkers and drug targets in cancer.
• To overcome the limitations of traditional mutation-based biomarker discovery in precision oncology.
• To summarize recent advancements and future directions in transcriptome-oriented data mining and phenotypic assays for cancer drug discovery.

Main Methods:

• Leveraging large-scale cancer transcriptome data for comprehensive analysis.
• Utilizing phenotypic screening assays to identify functional relationships and potential targets.
• Integrating transcriptome-level screening with physiologically relevant phenotypic assays for biomarker discovery.

Main Results:

• Transcriptome and phenotypic screening data present a significant opportunity for identifying novel biomarkers.
• Technological advancements facilitate rapid discovery of potential target-biomarker combinations.
• This approach can overcome limitations associated with analyzing low-frequency and varied mutation profiles.

Conclusions:

• Transcriptome-oriented data mining and phenotypic assays are crucial for identifying non-genetic biomarkers in cancer.
• These strategies offer a promising avenue for advancing precision cancer medicine and drug discovery.
• Future research should focus on integrating these approaches for robust biomarker and target identification.